Boehringer Ingelheim Venture Fund
Overview
The Boehringer Ingelheim Venture Fund is an evergreen fund established in 2010 that invests in pioneering science to redefine the standard of care and bring new medicines to patients.
Classification
- Headquarters
- Ingelheim am Rhein, Germany
- Geographic focus
- EU, US, China
- Stage
- any
- Fund status
- active
- Portfolio
- 1 companies
Fund details
- Fund size
- €350M
- AUM
- €350 M
- Check size
- €15M total
- Founded
- 2010
Thesis & focus
Access to BI’s R&D, labs, partnership networks, scientific expertise, business-growth acceleration, regulatory support
Agomab Therapeutics (IPO 2026), ImCheck Therapeutics (2025), Cardior Pharmaceuticals (2024), T3 Pharmaceuticals (2023), NBE Therapeutics (2020)
first-in-class, disease-modifying therapeutic
Committed to advancing scientific innovation
Investment thesis
We invest in pioneering science that aims to redefine the standard of care and bring new medicines to patients.
Portfolio companies
No portfolio companies linked yet.
Co-investors
Loading co-investment network…
No co-invest data available.
Source: vc_export
Website preview visit ↗
